Tags

Type your tag names separated by a space and hit enter

Mesalazine for diverticular disease of the colon--a new role for an old drug.
Expert Opin Pharmacother 2005; 6(1):69-74EO

Abstract

Colonic diverticulosis is among the most common diseases of developed countries. Its prevalence is approximately 5 - 10% of the population by age 50, and 30, 50 and 66% of those > 50, > 70 and > 85years of age, respectively. Antibiotics have been successfully used in the treatment of uncomplicated diverticular disease; however, the use of mesalazine (alone or in combination with antibiotics) in treating uncomplicated diverticulitis has been successfully developed in recent years. Indeed, mesalazine (with or without antibiotics) showed significant superiority in improving the severity of symptoms, bowel habits, and in preventing symptomatic recurrence of diverticulitis over antibiotics alone. More-over, in light of some preliminary results, it is probable that the association of mesalazine with probiotics may in the future be the first-choice treatment for mild-to-moderate uncomplicated attacks of acute diverticulitis.

Authors+Show Affiliations

Lorenzo Bonomo' Hospital, Digestive Endoscopy Unit, Andria (BA), Italy. antotursi@tiscali.it

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15709884

Citation

Tursi, Antonio. "Mesalazine for Diverticular Disease of the Colon--a New Role for an Old Drug." Expert Opinion On Pharmacotherapy, vol. 6, no. 1, 2005, pp. 69-74.
Tursi A. Mesalazine for diverticular disease of the colon--a new role for an old drug. Expert Opin Pharmacother. 2005;6(1):69-74.
Tursi, A. (2005). Mesalazine for diverticular disease of the colon--a new role for an old drug. Expert Opinion On Pharmacotherapy, 6(1), pp. 69-74.
Tursi A. Mesalazine for Diverticular Disease of the Colon--a New Role for an Old Drug. Expert Opin Pharmacother. 2005;6(1):69-74. PubMed PMID: 15709884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesalazine for diverticular disease of the colon--a new role for an old drug. A1 - Tursi,Antonio, PY - 2005/2/16/pubmed PY - 2006/4/7/medline PY - 2005/2/16/entrez SP - 69 EP - 74 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 6 IS - 1 N2 - Colonic diverticulosis is among the most common diseases of developed countries. Its prevalence is approximately 5 - 10% of the population by age 50, and 30, 50 and 66% of those > 50, > 70 and > 85years of age, respectively. Antibiotics have been successfully used in the treatment of uncomplicated diverticular disease; however, the use of mesalazine (alone or in combination with antibiotics) in treating uncomplicated diverticulitis has been successfully developed in recent years. Indeed, mesalazine (with or without antibiotics) showed significant superiority in improving the severity of symptoms, bowel habits, and in preventing symptomatic recurrence of diverticulitis over antibiotics alone. More-over, in light of some preliminary results, it is probable that the association of mesalazine with probiotics may in the future be the first-choice treatment for mild-to-moderate uncomplicated attacks of acute diverticulitis. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/15709884/Mesalazine_for_diverticular_disease_of_the_colon__a_new_role_for_an_old_drug_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.6.1.69 DB - PRIME DP - Unbound Medicine ER -